At least one NSCLC cell line with focally amplified FGFR1 requires the gene as demonstrated by shRNA depletion, and is also sensitive to inhibition with FGFR kinase inhibitors. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.